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Abstract
Background—Peripheral epigenetic marks hold promise for understanding psychiatric illness 
and may represent fingerprints of gene–environment interactions. We conducted an initial 
examination of CpG methylation variation in children with or without attention-deficit/
hyperactivity disorder (ADHD).
Methods—Children age 7–12 were recruited, screened, evaluated and assigned to ADHD or non-
ADHD groups by defined research criteria. Two independent age-matched samples were 
examined, a discovery set (n = 92, all boys, half control, half ADHD) and a confirmation set (n = 
20, half ADHD, all boys). 5-methylcytosine levels were quantified in salivary DNA using the 
Illumina 450 K HumanMethylation array. Genes for which multiple probes were nominally 
significant and had a beta difference of at least 2% were evaluated for biological relevance and 
prioritized for confirmation and sequence validation. Gene pathways were explored and described.
Results—Two genes met the criteria for confirmation testing, VIPR2 and MYT1L; both had 
multiple probes meeting cutoffs and strong biological relevance. Probes on VIPR2 passed FDR 
correction in the confirmation set and were confirmed through bisulfite sequencing. Enrichment 
analysis suggested involvement of gene sets or pathways related to inflammatory processes and 
modulation of monoamine and cholinergic neurotransmission.
Conclusions—Although it is unknown to what extent CpG methylation seen in peripheral tissue 
reflect transcriptomic changes in the brain, these initial results indicate that peripheral DNA 
methylation markers in ADHD may be promising and suggest targeted hypotheses for future study 
in larger samples.
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Introduction
ADHD, like most psychiatric disorders, lacks either a full account of its pathophysiology 
and mechanisms of development, or biological measures that reliably predict either liability 
or illness. Although ADHD has substantial heritability, the search for biological targets is 
increasingly informed by interest in whether the disorder is shaped by interactions between 
genotype and environmental factors (Nigg, Nikolas, & Burt, 2010; Purcell, 2002). The 
mechanism by which environmental factors or genotype by environment interactions might 
influence ADHD remains unknown.
One possibility is via dynamic epigenetic modifications to gene expression. Epigenetic 
modification, a normal part of tissue development, can occur not only spontaneously but 
also in response to environmental effects (implying genotype by environment interactions). 
As a result, an integrated genetic/epigenetic approach to understanding complex disease is 
emerging (Rakyan, Down, Balding, & Beck, 2011), although not without important cautions 
(Heijmans & Mill, 2012). The best understood epigenetic modification is DNA methylation, 
which influences gene expression via the disruption of transcription factor binding and the 
attraction of methyl-binding proteins that initiate chromatin compaction and gene silencing.
Epigenetic variation cannot be assessed in brain tissue from living people, so studies of 
living individuals must be undertaken using peripheral tissue. Although the degree of cross-
tissue concordance in DNA methylation remains in question, these studies still hold 
potential for novel discovery of liability markers or identify targets for future investigation 
in neural systems (Aberg et al., 2013; Horvath, 2013). Recent studies of peripheral tissue 
DNA methylation have identified epigenetic variation associated with autism (Berko et al., 
2014; Wong et al., 2013) and psychosis (Aberg et al., 2014; Dempster et al., 2011), with 
promising results. In ADHD, a small number of prior studies have examined DNA 
methylation in candidate genes (van Mil et al., 2014; Xu et al., 2015) with encouraging 
results. Methylome-wide epigenetic exploration in ADHD has yet to be conducted. The 
current report therefore describes the first methylome-wide study in childhood ADHD, using 
DNA derived from saliva samples in a pilot study design.
Methods
Participants and case identification
Families were recruited by soliciting community volunteers with public advertisements and 
mass mailings using commercial mailing lists. The local Institutional Review Board 
approved the studies. Parents provided written informed consent for themselves and their 
children and children provided written informed assent. All families underwent a multigate 
screening process to establish eligibility and diagnostic group assignment that included a 
parent–clinician clinical structured diagnostic parent interview (Schedule for Affective 
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Disorders and Schizophrenia for School-Age Children—Epidemiologic Version [KSAD-S-
E]; Puig-Antich & Ryan, 1996), parent and teacher standardized rating forms that assessed 
symptoms and impairment, clinician observations, and child completion of a short from of 
the Wechsler Intelligence Scales for Children-Fourth Edition (WISC-IV; Wechsler, 2003). 
All of this information was then presented to a clinical diagnostic team in order to 
implement a best estimate diagnostic procedure. Their agreement rate was acceptable for 
ADHD (k > .80; all subtypes were allowed) and for all disorders with base rate >5% in the 
study (k > .75). Disagreements were resolved by discussion.
Exclusion criteria—Exclusion criteria include an estimated Full Scale IQ < 75; diagnosis 
of current major depressive episode, lifetime mania or psychosis, pervasive developmental 
disorder (including autism), learning disability or major medical/neurological disorders or 
injuries.
Medication—Current prescription of any psychoactive medication, including any stimulant 
or nonstimulant preparation, with a half-life greater than 7 hr was exclusionary, due to an 
accompanying study of cognitive performance requiring medication washout. DNA samples 
obtained for the current analysis were obtained without medication washout in medicated 
cases (29 subjects, all on various stimulant preparations: Daytrana Patch, Adderall, 
Dexedrine Tablets, Focalin Tablets, Metadate ER Capsules, Methylin ER Tablets, Methylin 
Tablets, Adderal XR, Ritalin LA, Concerta, Vyvanse). Medication status was handled in 
covariance analysis as described in the data analysis section.
Generation of subsamples
For the present report, two subsamples were selected from the larger cohort for purposes of 
hypothesis generation (‘discovery’) and testing (‘confirmation’). The discovery sample 
comprised 92 boys, half with ADHD, (age range 7–11.8 and a mean of 8.7 years), of whom 
85 were retained in analysis after DNA quality control. Of the 85, 55% had been treated 
currently or in the past with stimulant medication. These individuals were allowed in to 
maximize representativeness, because medication status is positively correlated with ADHD 
severity in our sample as in others. Medication history is addressed statistically as explained 
below and by exclusion in the confirmation sample. A small confirmation sample was 
selected that comprised 20 never-medicated boys, 10 with ADHD and 10 without ADHD, 
with an age range of 7–11 and a mean of 9.0 years (Table 1, below).
Laboratory methods
DNA was extracted from salivary samples collected in Oragene® cups and extracted using 
the DNA Genotek PrepIt kit (DNA Genotek Inc., Kanata, ON, Canada) as per 
manufacturer’s protocols. Specimen concentration was determined using Pico-Green (Ahn, 
Costa, & Emanuel, 1996). Genome-wide DNA methylation was assessed with the Illumina 
Infinium HumanMethylation450 BeadChip (Bibikova et al., 2011) following sodium 
bisulfite treatment of genomic DNA. The first sample data set (n = 92) was assayed by 
Illumina, Inc. (San Diego, CA), and the second (N = 20) by Expression Analysis, Inc. 
(Durham, NC). Each data set was processed and analyzed independently.
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Data preprocessing and quality control
Specimen and data processing—DNA was processed at the respective facilities using 
in-house QC protocols for assay performance. Raw data were imported into Genome Studio 
(Illumina, Inc.) to investigate the sample hybridization quality and to extract the signal 
intensities for each probe.
Data preprocessing—Raw methylation values were examined for acceptable quality of 
probes and samples using custom scripts within the R statistical programming language 
(http://www.r-project.org) using packages from the Bioconductor software project (http://
www.bioconductor.org (Gentleman et al., 2004). Poorly performing probes and samples 
were removed from the dataset using the R package wateRmelon (Pidsley et al., 2013), 
including removal of probes with detection p-values >.05 for >1% across all samples; 
nonspecific probes and those containing polymorphic SNPs (Chen et al., 2013). Specimen 
samples were removed from the analysis if >1% of the total number of probes for that 
sample had detection p-values >.01. Six specimens failed in the first data set and one 
overlooked sibling was removed, leaving N = 85 for analysis (44 ADHD and 41 controls). 
The final probe number available after QC was 384,464 in the discovery sample and 
392,598 in the confirmation sample.
Within each data set, samples passing QC were normalized together across all batches, using 
wateRmelon (Pidsley et al., 2013). Raw intensity values for each chip were quantile-
normalized separately for the methylated and unmethylated signals. The average DNA 
methylation level (beta value) for each probe was calculated as the ratio of the normalized 
signal for the methylated signal to the sum of the normalized values of the methylated and 
unmethylated signals. Therefore, beta values range from 0 (unmethylated) to 1 (methylated).
Data analysis
Confounders and covariates—To correct for potential confounders, principal 
components analysis (PCA) was conducted on the normalized methylation values for each 
probe. The first principal component loading (99.1% of the variation for the discovery data 
set and 97% for the confirmation data set) was added to the analytic model. As it took up so 
much variation, it is likely that this principal component largely accounted for variation due 
to technical variation, spatial variation on the chip, saliva cell type variation between groups, 
ancestry variation between groups, as well as age and medication status. Supporting that 
impression, medication status, age, and race were unrelated to the first principle component, 
suggesting trivial associations with methylation values. Further supporting this point, 
secondary analyses were conducted with single covariates with no change in the primary 
conclusions. Based on the large amount of variance accounted for by the first principal 
component, additional corrections (such as statistical corrections for cell type or ancestry 
(Barfield et al., 2014; Houseman, Molitor, & Marsit, 2014), were not conducted to avoid 
power loss and collinearity as recommended by Barfield (Barfield et al., 2014).
Analysis—Differentially methylated probes (DMPs) were identified using custom R 
scripts. Each CpG site was tested individually in a linear regression model(Barfield, Kilaru, 
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Smith, & Conneely, 2012) in which normalized beta values represent the dependent variable 
and the ADHD status the independent predictor, adjusted for the first principal component.
Selection of DMPs for validation—Figure 1 schematizes the probe prioritization and 
testing strategy adopted for testing in our small sample to balance Type I and Type II error. 
We prioritized loci with multiple qualifying probes in the discovery set at nominal 
significance and beta difference between groups of at least 2% in the discovery set. We then 
focused on differentially methylated probes (DMPs) with identifiable biological relevance to 
ADHD through examination of the information libraries available through the Wiezman 
Institute of Science (http://www.genecards.org/) and NIH (www.ncbi.nih.-gov/IEB/
Research/Acembly). Potentially relevant genes were then scored on their relevance and 
prioritized based on prior literature on psychiatric disorders, animal models of knockouts 
related to ADHD symptoms, and expression in brain regions of particular interest in ADHD. 
Those selected were then limited to 10 probes to preserve power on the replication, based on 
qualitative examination of their theoretical relevance. They in turn were examined for 
nominal and FDR-corrected significance in the confirmation data set. Surviving probes 
underwent technical validation by sequencing.
Probe sequence validation—Targeted bisulfite sequencing was used to validate the 
DMPs. Primer design and validation were performed by Zymo Research Corporation 
(Irvine, CA) on bisulfite-converted control DNA. Primers were designed to flank each 
targeted CpG site in 100–300 nucleotide regions. Following primer validation, study 
specimen DNA was bisulfite converted using the EZ DNA Methylation-LightningTM Kit 
(Zymo Research). Samples were amplified and barcoded using the Fluidigm Access 
ArrayTM System and sequenced (MiSeq, Illumina, Inc., San Diego, CA) using the paired-
end sequencing protocol according to the manufacturer’s guidelines.
Sequence reads were identified using standard Illumina base-calling software. Low quality 
nucleotides and adapter sequences were trimmed off during analysis QC. Sequence reads 
were aligned back to the reference genome using default Bismark parameters (Krueger & 
Andrews, 2011). The methylation level of each sampled cytosine was estimated as the 
number of reads reporting a C, divided by the total number of reads reporting a C or T.
Quality control was performed on all specimens before and following bisulfite conversion. 
Two specimens had low sequencing depth and were discarded (see Table S1, available 
online, for details). Differential methylation was assessed per CpG site including samples 
with at least 10 reads. Multiple testing correction was done by the False Discovery Rate 
(FDR) procedure.
Supporting information
Additional Supporting Information may be found in the online version of this article:
Table S1. Quality control of targeted bisulfite sequencing.
Table S2. List of probes for which there was more than one probe per gene that was nominally significant.
Table S3. Sequencing validation results for VIPR2.
Table S4. Pathways enrichment analysis.
Figure S1. Distributions of VIPR2 cg 13444538 normalized methylation values of ADHD and non-ADHD boys.
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Pathway (enrichment) analysis—As noted in Figure 1, to explore biological 
significance, we conducted pathway or gene set enrichment analysis using the gene sets 
defined in (a) the Gene Ontology Biological Process Category (www.http://
geneontology.org/, http://www.broadinstitute.org/gsea/msigdb/index.jsp, 6/82014: c5 GO 
gene sets) and (b) the ConsensusPathdb (‘pathways’) (Kamburov, Stelzl, Lehrach, & 
Herwig, 2013), which includes protein–protein interactions, protein-DNA, and biochemical 
pathways such as signaling and metabolic pathways. Several methods exist for quantifying 
the association between functional groups of genomic variables and a clinical phenotype 
(Hung, Yang, Hu, Weng, & DeLisi, 2012; Khatri, Sirota, & Butte, 2012; Mooney, Nigg, 
McWeeney, & Wilmot, 2014). The methods used here were as follows.
Probes on the array were mapped to genes using the Illumina annotations. Because of the 
differences in number of probes per gene and the structure among them, we utilized a 
procedure that is robust to correlation structure among probes to generate gene level p-
values for each gene (Wu et al., 2010) resulting in 19,984 single gene p-values For 
enrichment analysis, we used a commonly used framework (Goeman & Buhlmann, 2007) 
wherein a ‘competitive’ gene set test compares genes in the test set relative to all other genes 
(Gatti, Barry, Nobel, Rusyn, & Wright, 2010).
However, intergene correlations among genes in different pathways (gene sets) inflate the p-
value and the apparent false discovery rate (Gatti et al., 2010). To address this, we utilized a 
method that adjusts for the correlation among the genes to allow for differences in the 
correlation structure of each gene set (Wu & Smyth, 2012). Normalized methylation values 
for all genes in the data set were used to generate the correlation among all genes. A 
variation inflation factor was then calculated and used to adjust for these correlations. Each 
defined gene set was tested for enrichment of differentially methylated genes 
(hypermethylated and hypomethylated combined) relative to genes not in the gene set using 
the function ‘camera’ in the limma R package (Ritchie et al., 2015). After analysis, results 
were separated into gene sets containing >50% genes that were hypomethylated in ADHD 
and gene sets containing >50% genes that were hypermethylated in ADHD for ease of 
viewing and interpretation. We interpreted gene sets with nominal p ≤ .01 for purposes of 
developing hypotheses for future studies.
Results
Demographic and clinical descriptions of the discovery and confirmation cohorts are 
provided in Table 1. The sample is typical of many ADHD studies in clinical severity, 
comorbidity, and demographic profile.
Prioritization
We identified 95 genes with >1 annotated DMP (n = 245 DM probes) (at a nominal p-value 
of p < .05 and a beta difference >2%) (Table S2). Among the 95 genes were several known 
to be expressed in brain and to have prior associations with behavior, neurodevelopment, 
and/or psychiatric illness and thus to be particularly biologically relevant to ADHD, 
including: neuron navigator 1 (NAV1), ninjurin2 (NINJ2), solute carrier family 12, member 
9 (SLC12A9), vasoactive intestinal peptide receptor 2 (VPR2), myelin transcription factor 1-
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like (MYT1L), oxytocin receptor (OXTR), histone deacetylase 4 (HDAC4), and major 
histocompatibility complex genes (HLA-A, HLA-B, HLA-C). With the goal of limiting the 
replication test to enhance power for multiple testing correction, we selected a small subset 
of these based on literature review and those having the most elements relevant to our study, 
including (1) relevant animal models, (b) prior association to psychiatric illness, (c) 
association with neural development, (d) known expression in well studied brain regions 
identified in ADHD. The top-rated two genes chosen were VIPR2 and MYT1L. VIPR2 
(7q36.3) was prioritized because it met the following criteria: (a) expression in the caudate, 
a key ADHD-relevant brain area, (b) animal knockout model in which underexpression is 
associated with hyperactivity (Sheward et al., 2010), and (c) associated with psychiatric 
disorder (Levinson et al., 2011). MYT1L (2p25.3) was selected for (a) its potential 
involvement in myelin formation and nervous system formation, of interest to our group due 
to our work on white matter formation in ADHD (Nagel et al., 2011), and (b) because of its 
prior association with both major depressive disorder (Wang et al., 2010) and schizophrenia 
(Pidsley et al., 2014).
Confirmation set
Six of the probes from these two genes were present in the second, confirmation cohort 
(Table 2). The MYT1L probes failed to meet our confirmation standard of FDR p < .05, but 
we did confirm the association in the same direction for probe cg13444538 in VIPR2 
(discovery beta difference = −.059, p = .0345; confirmation beta difference = −.0964, p = .
0064, FDR = .0386). Two other VIPR2 probes trended close to confirmation: cg08479516 
(discovery beta difference = −.0321, p = .0256; confirmation beta difference = −.0472, p = .
0169, FDR = .058) and cg05554000 (discovery beta difference = −.0537, p = .0199; 
confirmation beta difference = −.0692, p = .0608, FDR = .093). All probes indicated 
hypomethylation in VIPR2 for ADHD samples. Differences in probe cg13444538 
methylation value distributions for each cohort set are shown in Figure S1.
Technical validation by sequencing
Amplicons were generated to cover 250 base pairs 5′ and 3′ of the three VIPR2 replicated 
probes. Targeted bisulfite sequencing was used to profile DNA methylation across 73 CpG 
sites, for which 43 sites were significantly hypomethylated in ADHD subjects after 
correction for multiple testing (FDR p = .000007 to p = .041, Table S3). Two intronic 
regions of VIPR2 were covered by sequencing, (Figure 2).
Gene pathways and enrichment analysis
The functional relationship among the differentially methylated genes was assessed for 
enrichment of a particular functional category using the GO Biological Process gene and 
pathways as defined in the ConsensusPathDB. For the GO Biological Process category gene 
sets, we found six signatures associated with ADHD using an unadjusted p ≤ .01 (Table 3). 
The hypomethylated set revealed sets involved in anti-oxidant activity. The top two 
hypermethylated sets involved nicotinic receptor activity. ConsensusPathDB pathways were 
tested for enrichment in the same manner. Of 3669 Canonical pathways tested, 34 showed 
nominal (p < .01) differences in methylated genes (Table S4). Hypomethylated pathways 
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included homocysteine, cysteine, glutathione, and fatty acid oxidation pathways, all related 
to inflammatory mechanisms and thus potentially related to the hypomethylated process 
categories. Hypermethylated pathways included glutamine degradation and G-protein 
signaling pathways, and thus potentially related to the hypermethylated process categories.
Covariate assessment
To confirm our assumptions about the PCA approach, post hoc checks on the surviving final 
probes were conducted while directly covarying age, history of simulant medication use, and 
race. These results did not change results or conclusions meaningfully and so were not 
presented. Sequence validation results were also retested post hoc with these same 
covariates (PCA is inapplicable to the targeted gene approach), with no meaningful change 
in the results presented earlier.
Discussion
The examination of peripheral DNA methylation patterns in psychiatric disease is of interest 
as a potential liability or disease biomarker and as a clue to etiology. Here, we present the 
first methylome-wide exploration of DNA methylation in peripheral tissue, examining 
salivary DNA from children with ADHD relative to non-ADHD controls.
Probes in VIPR2 showed lower CpG methylation in the saliva of children with ADHD, a 
finding that was supported by our additional tests. VIPR2 encodes the Vasoactive intestinal 
peptide receptor 2 and is expressed throughout the central nervous system and the periphery
—a useful feature of a marker to be studied in this way. SNPs in VIPR2 have been 
associated previously with mood disorder (Soria et al., 2010) while duplications in VIPR2 
have been seen in schizophrenia (Levinson et al., 2011; Vacic et al., 2011). Low-copy 
repeats within VIPR2 have been identified as having a role in the 7q36.3 genomic 
rearrangements in a patient with mild mental retardation and were also found as both simple 
and complex structural polymorphisms associated with the VIPR2-LCR region (Beri, 
Bonaglia, & Giorda, 2013). Mutations in the VIPR2 homolog in the mouse cause 
hypoactivity, as well as disruptions in circadian rhythm (Eppig, Blake, Bult, Kadin, & 
Richardson, 2012), thus decreased methylation might be speculated to increase 
hyperactivity. Circadian hormones are of ongoing interest in relation to ADHD (Chaste et 
al., 2011) as well.
The pathway enrichment analysis here were exploratory only; they suggested that future 
studies might hypothesize differential methylation gene sets that (a) regulate inflammation 
and cell damage via oxidation and anti-oxidation, (b) lie in the biological pathways related 
to the methionine cycle and glutathione metabolism and (c) in relation to cross-modulation 
of Ach, glutamatergic, and/or G-protein modulated neurotransmitter systems. Recent work 
on the effects of maternal and child nutrition on neural development (Bhatia et al., 2011; 
Chen & Su, 2013; Janssen et al., 2015) suggests that anti-inflammatory long chain fatty acid 
intake is protective against inflammation risk. A recent meta-analysis reports that children 
with ADHD have reduced blood levels of these important nutrients and appear to benefit 
from supplementation (Gow & Hibbeln, 2014; Hawkey & Nigg, 2014; Widenhorn-Muller, 
Schwanda, Scholz, Spitzer, & Bode, 2014). Second, G-protein coupled receptors are of 
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interest in relation to brain neurotransmitter function and have recently been proposed to 
have implications for dopaminergic and glutamatergic neurotransmission (Garcia-Olivares 
et al., 2013; Lesch, Merker, Reif, & Novak, 2013; Xie et al., 2012). The cross-talk of 
cholinergic and glutamatergic systems is already widely studied (Grupe et al., 2013; Gu et 
al., 2014; Nelson, Bussert, Kreitzer, & Seal, 2014; Pancani et al., 2014; Pidoplichko, Prager, 
Aroniadou-Anderjaska, & Braga, 2013), but likewise underexamined in ADHD.
Thus, a third more focused hypothesis generated by those explorations involves epigenetic 
modulation of cholinergic or nicotinic receptor functioning. This focus may be particularly 
intriguing in light of the recent interest in those receptors’ role in prefrontal cortical 
function, impulsivity, and attention (Lee, Fuemmeler, McClernon, Ashley-Koch, & Kollins, 
2013; Ohmura, Tsutsui-Kimura, & Yoshioka, 2012; Sterley, Howells, & Russell, 2014; 
Wallace & Bertrand, 2013), recent genetic findings related to ADHD and cholinergic 
receptor genes (Williams et al., 2012), and interest in the role of nicotinic receptor 
intervention as an effective and novel treatment target for ADHD in animal and human trials 
(Bain et al., 2012; Potter, Dunbar, Mazzulla, Hosford, & Newhouse, 2014).
ADHD status in the children from whom saliva was analyzed in this study was very well 
characterized. Although half of the children in the initial sample were treated with stimulant 
medication, methylation differences were not dependent on medication status.
The results should be viewed with caution for several reasons in addition to the small 
samples, which may have resulted in failure to confirm MYT1L. The decision to prioritize 
probes for replication and validation based on the significance of multiple probes per gene 
could result in overlooking important signals in the data from single probes. Relatedly, we 
opted to use a larger sample for discovery than replication to maximize our power to identify 
putative methylation affects, knowing that we would be testing only a very small set of 
probes for replication. However, a larger confirmation study might result in more reliable 
estimates (Duncan & Keller, 2011). Second, although we excluded probes known to be 
located in SNPs, a full accounting of epigenetic effects requires formal genetic control, by 
either analysis of genotyped data or twin studies, which we are currently undertaking. 
Likewise, we did not examine mRNA expression in relation to sites identified; that is, a 
study we are undertaking in future. While it is likely that the PCA accounted for cell type 
variation (Barfield et al., 2014), cell types were not directly examined and should be directly 
evaluated to fully understand the meaning of peripheral tissue findings in future work. 
Likewise, ancestry was not examined genetically although is unlikely to account for effects 
based again on the large amount of variation accounted for in the first principal component 
here (Barfield et al., 2014).
Other analytic methods such as differential methylation region analysis, could also be 
considered in future larger studies. Sex differences do not account for results because only 
boys were included, but results cannot be generalized to girls. Finally, we cannot draw 
conclusions from these data about patterns of DNA methylation, nor changes in gene 
function, within the brain (Davies et al., 2012; Horvath, 2013).
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In conclusion, the present results provide initial evidence that ADHD is associated with 
differential methylation in genes relevant to children’s activity levels. The findings provide 
hypotheses to guide further study and help open the door for new work in this area. We 
conclude that VIPR2 is an interesting novel target for ADHD research and that further study 
of peripheral tissue methylation in ADHD is promising.
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Key points
• Study of DNA methylation is a growing strategy for understanding roots of 
psychopathology; DNA methylation can occur in response to early experience 
and suggest one mechanism for gene by environment interplay in development.
• Prior studies have looked at candidate genes but this is the first methylome-wide 
study of DNA methylation in child psychopathology.
• Results identified and validated an association of ADHD diagnosis with reduced 
DNA methylation in the VIPR2 gene, which is associated with circadian rhythm 
and with activity level in an animal model and has also been previously 
identified in a study of DNA methylation in schizophrenia.
• Gene pathways related to neurotransmitters and neural development were 
identified for future research.
• This is a pilot study; results are strictly preliminary due to a very small sample. 
However, they illustrate that this approach to understanding ADHD may be 
fruitful and suggest promising hypotheses for follow up work.
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Figure 1. 
Work flow for probe prioritization. In the discovery set genes were prioritized if more than 
one probe was nominally significant at a moderate effect size (beta difference ≥.02). These 
were further prioritized based on brain expression and animal models. A small probe set was 
selected for confirmation testing in a second cohort of children. Surviving probes underwent 
technical sequence validation
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Figure 2. 
VIPR2 Targeted bisulfate sequence validation. (Panel A) VIPR2 gene models indicating the 
genomic locations for the probes targeted for validation. All probes were located in two CpG 
islands shown in green. (Panel B and C) Individual sample methylation ratios for ADHD 
(red) and control (blue) specimens. p-Values for differential methylation between ADHD 
and controls is shown per CpG tested
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Table 1
Descriptive and diagnostic statistics for ADHD and control groups
Sample A (N = 85) Sample B (N = 20)
Variable ADHDc (n = 43) Control (n = 42) ADHD (n = 10) Control (n = 10)
Age (months; mean, SD) 116.2 (17.1) 116.7 (17.1) 98.2 (7.4) 100.1 (9.1)
Gender (% male) 100% 100% 100% 100%
Race (% White) 97.60% 92.90% 90% 70%
Family income ($K; mean, SD) 67.9 (31.0) 72.2 (30.5) 68.5 (25.6) 68.5 (30.0)
WISC-IVa FSIQb (mean, SD) 113.5 (11.9) 117.0 (12.8) 110.2 (13.9) 117.6 (9.6)
Conner’s 3rd edition (T-score)
  Parent-rated cognitive (Inattention) 73.4 (11.2) 45.6 (5.8)* 74.6 (12.7) 46.1 (5.9)*
  Parent-rated hyperactive/Imp. 77.8 (10.3) 46.1 (7.4)* 78.1 (10.5) 46.7 (8.0)*
  Teacher-rated cognitive (Inattention) 65.7 (10.0) 45.5 (4.9)* 63.4 (8.7) 44.9 (4.7)*
  Teacher-rated hyperactive/Imp. 73.5 (13.7) 45.0 (4.9)* 75.4 (8.9) 44.1 (4.7)*
Comorbid disorders (K-SADS-Ed)
  Lifetime any mood disorder 11.60% 0.00% 10.00% 0.00%
  Any anxiety disorder 9.30% 7.00% 10.00% 10.00%
  Conduct disorder 0.00% 0.00% 0.00% 0.00%
  Oppositional defiant disorder 23.30% 2.3%* 30.00% 0.0%*
aWISC-IV: Wechsler Intelligence Scales for Children.
b
Full-Scale Intelligence Quotient (estimated).
cAttention-Deficit/Hyperactivity Disorder Rating Scale.
d
Kiddie Schedule of Affective Disorders and Schizophrenia.
*Group difference within sample at p < .05.
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Table 3
GO Biological Process (BP). (A) Gene sets more hypomethylated in ADHD than other gene sets in the GO BP 
and (B) GO Genes sets more hypermethylated in ADHD than other GO Gene sets
N Genesa Correlationb p-valuec GO gene set
(A)
  151 .0055 .000 OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PEROXIDE_AS_ACCEPTOR
  239 .0013 .001 NEGATIVE_REGULATION_OF_ANGIOGENESIS
  247 .0047 .003 ANTIOXIDANT_ACTIVITY
  205 .0037 .009 CASPASE_REGULATOR_ACTIVITY
(B)
  154 .0001 .009 NICOTINIC_ACETYLCHOLINE_GATED_RECEPTOR_CHANNEL_COMPLEX
  154 .0001 .009 NICOTINIC_ACETYLCHOLINE_ACTIVATED_CATION_SELECTIVE_CHANNEL_ACTIVITY
aNumber of genes in the gene set.
bCorrelation among the genes in the gene set.
c
p-values are uncorrected; none of these effects would be significant at FDR p < .05.
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